Antibody evasion by the P.1 strain of SARS-CoV-2

Antibody evasion by the P.1 strain of SARS-CoV-2

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7...

Полное описание

Библиографические подробности
Главные авторы:	Dejnirattisai, W, Zhou, D, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Levin, R, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Paterson, NG, Williams, MA, Hall, DR, Hulswit, RJG, Bowden, TA, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR
Формат:	Journal article
Язык:	English
Опубликовано:	Cell Press 2021

Схожие документы

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
по: Zhou, D, и др.
Опубликовано: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
по: Liu, C, и др.
Опубликовано: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
по: Supasa, P, и др.
Опубликовано: (2021)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
по: Nutalai, R, и др.
Опубликовано: (2022)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
по: Liu, C, и др.
Опубликовано: (2021)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
по: Dejnirattisai, W, и др.
Опубликовано: (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
по: Tuekprakhon, A, и др.
Опубликовано: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
по: Huo, J, и др.
Опубликовано: (2022)

Integrative structural biology of viruses
по: Duyvesteyn, HME
Опубликовано: (2019)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
по: Dejnirattisai, W, и др.
Опубликовано: (2021)

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
по: Daming Zhou, и др.
Опубликовано: (2024-03-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
по: Aiste Dijokaite-Guraliuc, и др.
Опубликовано: (2022-11-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
по: Flaxman, A, и др.
Опубликовано: (2021)

The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
по: Napas Taechasan, и др.
Опубликовано: (2024-07-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
по: Watanabe, Y, и др.
Опубликовано: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
по: Ragonnet-Cronin, M, и др.
Опубликовано: (2023)

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
по: McNaughton, AL, и др.
Опубликовано: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
по: Marchevsky, NG, и др.
Опубликовано: (2022)

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
по: Peng, Y, и др.
Опубликовано: (2020)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
по: Yasunori Watanabe, и др.
Опубликовано: (2021-04-01)

Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
по: Renner, M, и др.
Опубликовано: (2018)

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
по: Fernandez, E, и др.
Опубликовано: (2017)

The antigenic anatomy of SARS-CoV-2 receptor binding domain
по: Dejnirattisai, W, и др.
Опубликовано: (2021)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
по: Jiandong Huo, и др.
Опубликовано: (2022-11-01)

Evolution of neurovirulent Zika virus
по: Screaton, G, и др.
Опубликовано: (2017)

Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
по: Screaton, G, и др.
Опубликовано: (2018)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
по: Townsend, A, и др.
Опубликовано: (2021)

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
по: Sharpe, HR, и др.
Опубликовано: (2020)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
по: Sheerin, D, и др.
Опубликовано: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
по: Manon Ragonnet-Cronin, и др.
Опубликовано: (2023-06-01)

Accelerating drug target inhibitor discovery with a deep generative foundation model
по: Chenthamarakshan, V, и др.
Опубликовано: (2023)

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
по: Faria, NR, и др.
Опубликовано: (2021)

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
по: Midgley, C, и др.
Опубликовано: (2012)

Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.
по: Elodie Décembre, и др.
Опубликовано: (2014-10-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
по: Folegatti, PM, и др.
Опубликовано: (2020)

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
по: Chang Liu, и др.
Опубликовано: (2024-04-01)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
по: Alexander Rouvinski, и др.
Опубликовано: (2017-05-01)

Humidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virus.
по: Chotiyarnwong, P, и др.
Опубликовано: (2007)

Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine
по: Tsai, W, и др.
Опубликовано: (2018)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
по: Voysey, M, и др.
Опубликовано: (2023)